The company reported a 17% revenue growth in Q1 FY24, driven by international expansion and the Motif Labs acquisition, despite missing expectations. Organigram's balance sheet is robust with C$46 ...

About Organigram Holdings Inc. This news release ... s positioning to capture additional market share and sales including international sales, expectations for consumer demand, expected ...

The Jupiter Pool was designed to accelerate Organigram’s international growth ambitions and targets investments both overseas and in the United States. All potential investments will undertake ...

Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend ...

Organigram reported improved financial results for Q1-2025. OGI expects revenue to increase for Q2 as well as cash positions. OGI:CA sees growth in its international cannabis sales and Canadian sales.

OrganiGram Holdings, Inc. engages in the provision of high-quality, indoor-grown cannabis for patients and adult recreational consumers and developing international business partnerships to extend ...

Alliance Global Partners analyst Aaron Grey lowered the firm’s price target on Organigram (OGI) to C$3 from C$4.25 and keeps a Buy rating on the shares. The company’s Q1 results were below ...

The growth was largely due to an increase in recreational cannabis and international sales. OrganiGram said that integration of Motif Labs is progressing as planned, with over C$10 million in ...